Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery

Trapani, Adriana; Giglio, Elvira De; Cafagna, D.; Denora, Nunzio; Agrimi, Gennaro; Cassano, Tommaso; Gaetani, Silvana; Cuomo, V.; Trapani, Giuseppe

doi:10.1016/j.ijpharm.2011.07.036

Cited by 192 publications

(102 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An improvement in DA transport across the cells and oxygen reactive species reduction after 3 hours was observed. In vivo microdialysis studies administrating intraperitoneal DA-Cs-NP demonstrated a dose-and timedependent striatal DA level increase [15].…”

Section: Dss For Dopamine Deliverymentioning

confidence: 93%

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

2013

View full text Add to dashboard Cite

Current treatments for Parkinson's disease (PD) are aimed at addressing motor symptoms but there is no therapy focused on modifying the course of the disease.Successful treatment strategies have been so far limited and brain drug delivery remains a major challenge that restricts its treatment. This review provides an overview of the most promising emerging agents in the field of PD drug discovery, discussing improvements that have been made in brain drug delivery for PD. It will be shown that new approaches able to extend the length of the treatment, to release the drug in a continuous manner or to cross the blood brain barrier and target a specific region are still needed.Overall, the results reviewed here show that there is an urgent need to develop both symptomatic and disease-modifying treatments, giving priority to neuroprotective treatments. Promising perspectives are being provided in this field by rasagiline and by neurotrophic factors like glial cell line-derived neurotrophic factor. The identification of disease-relevant genes has also encouraged the search for disease-modifying therapies that function by identifying molecularly-targeted drugs. The advent of new molecular and cellular targets like α-synuclein, leucine-rich repeat serine/threonine protein kinase 2 or parkin, among others, will require innovative delivery therapies. In this regard, drug delivery systems (DDS) have shown great potential for improving the efficacy of conventional and new PD therapy and reducing its side effects. The new DDS discussed here, which include microparticles, nanoparticles and hydrogels among others, will probably open up possibilities that extend beyond symptomatic relief. However, further work needs to be done before DDS become a therapeutic option for PD patients.

show abstract

Section: Dss For Dopamine Deliverymentioning

confidence: 93%

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

2013

View full text Add to dashboard Cite

show abstract

“…The EE and LC of BRC-loaded CS NPs were 84.2 ± 3.5 and 37.8 ± 1.8%, respectively. The mean zeta potential of BRC-loaded CS NPs was found to be +40.32 ± 2.78 mV, which revealed that prepared formulations were stable [31]. The surface morphology of CS NPs recorded from SEM was either spherical or ellipsoidal with smooth surface (figure not shown) [15].…”

Section: Preparation and Characterisation Of Npsmentioning

confidence: 95%

Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method

Shadab

Haque

Fazil

et al. 2014

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Thus, new L-dopa formulation using NPs has been proposed: chitosan-coated NPs [197] and tested in vitro for toxicity [198]. An intrathecal implanted system allowing a site-specific controlled release of cellulose acetate phthalate NPs loaded with dopamine during a period of time was designed and evaluated in a rat model for the establishment of PD chronic drug delivery system [199].…”

Section: Therapeutic Strategies Using Nanoparticles In Ndmentioning

confidence: 99%

The Ins and Outs of Nanoparticle Technology in Neurodegenerative Diseases and Cancer

Wilson¹,

Magnaudeix²,

Naves³

et al. 2015

CDM

View full text Add to dashboard Cite

Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery

Cited by 192 publications

References 34 publications

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method

The Ins and Outs of Nanoparticle Technology in Neurodegenerative Diseases and Cancer

Contact Info

Product

Resources

About